Nestlé S.A. : New US acquisition for Nestlé Health Science will strengthen Brain Health and Metabolic Health portfolios with

  Nestlé S.A. : New US acquisition for Nestlé Health Science will strengthen
     Brain Health and Metabolic Health portfolios with new medical foods

Nestlé S.A. / New US acquisition for Nestlé Health Science will strengthen
Brain Health and Metabolic Health portfolios with new medical foods .
Processed and transmitted by Thomson Reuters ONE. The issuer is solely
responsible for the content of this announcement.

Nestlé Health Science, a fully owned subsidiary of Nestlé, has agreed to
acquire the business of Pamlab, a US-based company with an innovative
portfolio of medical food products for use under medical supervision in the
nutritional management of patients with mild cognitive impairment, depression
and diabetic peripheral neuropathy.

Strategic fit
The acquisition further strengthens Nestlé Health Science's capacity to
deliver personalised healthcare to address chronic medical conditions through
nutrition, especially in the areas of metabolic health and brain health.

"The acquisition of the Pamlab business is aligned with our strategic ambition
to provide science-based nutritional solutions for people with chronic medical
conditions. Pamlab will particularly strengthen our brain health platform and
provide us an additional foothold in metabolic health in the US," said Luis
Cantarell, Nestlé Health Science President and Chief Executive Officer.

"By leveraging our nutrition heritage and US operations with Pamlab's proven
expertise in medical foods and strong sales force capabilities, together we
can play a key role in helping to manage certain chronic diseases and improve
the quality of patients' lives," he added.

Commercialised products that improve quality of life
Pamlab's portfolio of prescription medical food products for use under medical
supervision includes Metanx, one of their key products that is formulated to
meet the distinct nutritional requirements of patients with diabetes to help
restore the metabolic processes associated with peripheral neuropathy.

This serious condition is common among those with Type 2 Diabetes, where the
patient's peripheral blood flow has been compromised and their nerves damaged.

Pamlab also makes Deplin, a medical food specifically formulated to provide
necessary nutritional support for certain people on prescribed antidepressant
therapy for clinical depression.

Deplin contains l-methylfolate, the active ingredient of folate, to help
balance three neurotransmitters associated with mood: serotonin, dopamine and
norepinephrine.

In addition, the company produces CerefolinNAC, a medical food to help address
distinct metabolic nutritional needs associated with mild cognitive
impairment.

A common purpose
"We are excited to join forces with Nestlé Health Science, and we share their
commitment to personalised nutrition," said Eric Wingerter, Pamlab President
and Chief Executive Officer.

"With their support, we will accelerate the development and deployment of our
innovative nutritional solutions for people with chronic metabolic and
neurologic conditions.
"We are united by a common purpose, and a common culture, founded on our
passion for patients to make a difference in people's lives."

Building on ambition towards science-based nutritional solutions
Nestlé Health Science's core business provides nutritional solutions for
people with specific dietary needs related to illness or disease states in the
area of ageing medical care, critical care and surgery, and paediatric medical
care.

The company is also developing new approaches to chronic diseases in the areas
of gastrointestinal (GI) health, metabolic health and brain health.

In 2012 Nestlé Health Science agreed to form a 50/50 joint venture named
Nutrition Science Partners, Ltd to develop nutritional and medicinal products
derived from botanical plants to address gastrointestinal disorders. This
transaction is subject to regulatory approval.

Other acquisitions and partnerships include: Prometheus Laboratories, a U.S.
firm specialising in diagnostics and licensed speciality pharmaceuticals in GI
and oncology; Vitaflo, a provider of clinical nutritional solutions for
infants, children and adults with genetic disorders that affect how food is
processed by the body; and a minority investment in U.S firm Accera,
specialising in medical foods intended for the clinical dietary management of
mild to moderate Alzheimer's disease.

Terms of acquisition
The terms of Nestlé Health Science's acquisition of Pamlab are not being
disclosed. The transaction is subject to regulatory approval.

Media enquiries
Tel: +41 21 924 2200
Email: mediarelations@nestle.com

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Nestlé S.A. via Thomson Reuters ONE
HUG#1680988

--- End of Message ---

Nestlé S.A.
Avenue Nestlé 55 Vevey

WKN: 887208;ISIN: CH0038863350;
 
Press spacebar to pause and continue. Press esc to stop.